💊 STOCK TO WATCH 💊
₹1,060–1,070 → ₹1,462 → ₹2,888 👀
A pharma/CDMO name appearing on my Weekly R4 Momentum Breakout Scanner.
Windlas Biotech Ltd.
📌 Buy Zone: ₹1,060–1,070
📌 Breakout Zone: ₹1,056
🛑 Stop Loss: ₹751
🎯 Target 1: ₹1,462
🎯 Target 2: ₹2,888
Why Windlas Biotech?
🧬 CDMO + formulations play: Windlas operates across generic formulations CDMO, domestic trade generics/institutional sales and exports, giving it multiple revenue engines.
🌍 Growing export opportunity: FY25 export revenue grew 19% YoY to ₹32.6 Cr, with 69 products exported to global partners.
🏭 Regulated manufacturing base: Its facilities include WHO-GMP-approved plants, with Plant 4 approved for markets including Europe, Canada and South Africa; Plant 5 adds injectable manufacturing capability.
💊 Complex-generic opportunity: The company is expanding product-development and manufacturing capabilities in complex generics and specialised dosage forms.
📈 Strong operating track record: Windlas reported Q1 FY26 revenue of ₹210 Cr, EBITDA ₹27 Cr and PAT ₹18 Cr, with YoY growth of 20%, 27% and 31%, respectively.
Why It Caught My Attention
✅ CDMO + branded formulations + exports
✅ Complex-generic opportunity
✅ WHO-GMP manufacturing infrastructure
✅ Injectable manufacturing capability
✅ Growing international presence
✅ Strong recent operating momentum
🔥 Weekly R4 Momentum Breakout
⚠️ HIGH RISK – HIGH REWARD SETUP. The technical levels above are your scanner-defined levels. The ₹751 stop-loss should be treated as the risk-control point, while execution, margins and export growth need continued monitoring.
Risk Defined. Reward Visible.
📢 Disclaimer: This content is for educational purposes only and not investment advice. Please do your own due diligence before making any investment decisions.
© 20K Microcap Investing | R4 Momentum Desk
#WindlasBiotech #WINDLASS #PharmaStocks #CDMO #PharmaceuticalStocks #ComplexGenerics #SmallCapStocks #HealthcareStocks #StockMarketIndia #IndianStocks #StocksToWatch #R4Breakout #MomentumInvesting #20KMicrocap
₹1,060–1,070 → ₹1,462 → ₹2,888 👀
A pharma/CDMO name appearing on my Weekly R4 Momentum Breakout Scanner.
Windlas Biotech Ltd.
📌 Buy Zone: ₹1,060–1,070
📌 Breakout Zone: ₹1,056
🛑 Stop Loss: ₹751
🎯 Target 1: ₹1,462
🎯 Target 2: ₹2,888
Why Windlas Biotech?
🧬 CDMO + formulations play: Windlas operates across generic formulations CDMO, domestic trade generics/institutional sales and exports, giving it multiple revenue engines.
🌍 Growing export opportunity: FY25 export revenue grew 19% YoY to ₹32.6 Cr, with 69 products exported to global partners.
🏭 Regulated manufacturing base: Its facilities include WHO-GMP-approved plants, with Plant 4 approved for markets including Europe, Canada and South Africa; Plant 5 adds injectable manufacturing capability.
💊 Complex-generic opportunity: The company is expanding product-development and manufacturing capabilities in complex generics and specialised dosage forms.
📈 Strong operating track record: Windlas reported Q1 FY26 revenue of ₹210 Cr, EBITDA ₹27 Cr and PAT ₹18 Cr, with YoY growth of 20%, 27% and 31%, respectively.
Why It Caught My Attention
✅ CDMO + branded formulations + exports
✅ Complex-generic opportunity
✅ WHO-GMP manufacturing infrastructure
✅ Injectable manufacturing capability
✅ Growing international presence
✅ Strong recent operating momentum
🔥 Weekly R4 Momentum Breakout
⚠️ HIGH RISK – HIGH REWARD SETUP. The technical levels above are your scanner-defined levels. The ₹751 stop-loss should be treated as the risk-control point, while execution, margins and export growth need continued monitoring.
Risk Defined. Reward Visible.
📢 Disclaimer: This content is for educational purposes only and not investment advice. Please do your own due diligence before making any investment decisions.
© 20K Microcap Investing | R4 Momentum Desk
#WindlasBiotech #WINDLASS #PharmaStocks #CDMO #PharmaceuticalStocks #ComplexGenerics #SmallCapStocks #HealthcareStocks #StockMarketIndia #IndianStocks #StocksToWatch #R4Breakout #MomentumInvesting #20KMicrocap
คำจำกัดสิทธิ์ความรับผิดชอบ
ข้อมูลและบทความไม่ได้มีวัตถุประสงค์เพื่อก่อให้เกิดกิจกรรมทางการเงิน, การลงทุน, การซื้อขาย, ข้อเสนอแนะ หรือคำแนะนำประเภทอื่น ๆ ที่ให้หรือรับรองโดย TradingView อ่านเพิ่มเติมใน ข้อกำหนดการใช้งาน
คำจำกัดสิทธิ์ความรับผิดชอบ
ข้อมูลและบทความไม่ได้มีวัตถุประสงค์เพื่อก่อให้เกิดกิจกรรมทางการเงิน, การลงทุน, การซื้อขาย, ข้อเสนอแนะ หรือคำแนะนำประเภทอื่น ๆ ที่ให้หรือรับรองโดย TradingView อ่านเพิ่มเติมใน ข้อกำหนดการใช้งาน